Trial Profile
Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Optic nerve disorders
- Focus Therapeutic Use
- Acronyms TONTT-2
- 08 Aug 2022 Status changed from recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 1 May 2021 to 1 Dec 2022.
- 02 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Aug 2022.